(Reuters) — McKesson Corp. and two other drug distributors could be expected to pay up to $21 billion for the potential settlement of lawsuits alleging the companies fueled the U.S. opioid epidemic, the company said on Tuesday.
The news came after McKesson, AmerisourceBergen and Cardinal Health in October 2019 proposed paying a combined $18 billion to resolve the 3,000-plus lawsuits, with the drugmaker Johnson & Johnson paying $4 billion.
McKesson would pay about $8 billion over 18 years as part of a proposed framework for settlement by a group of attorneys general, the company said in a filing.
